Cancer remains one of the most formidable health challenges worldwide, affecting millions every year.
According to a study by Cancer Research UK, it’s estimated that there were 18.1 million new cancer diagnoses globally in 2020. This alarming figure underscores the rising trend in cancer diagnoses, the study states, “Worldwide there will be 28 million new cases of cancer each year by 2040.”
It’s not just about the overwhelming statistics but its profound impact on patients and their families. The treatment landscape, although progressing, still yearns for innovative breakthroughs.
NANOBIOTIX and NBTXR3
NANOBIOTIX, a biotechnology firm aiming to provide new treatment solutions for cancer patients, has recently welcomed Dr. Louis Kayitalire as their chief medical officer. Dr. Kayitalire boasts a prolific background in the biopharmaceutical sector, primarily focusing on oncology. He has been an integral part of the development and commercialization of various oncology therapeutics.
Laurent Levy, co-founder and chairman of NANOBIOTIX, praised Dr. Kayitalire’s innovative clinical acumen, asserting that his experience would be paramount in forwarding the company’s ventures, especially regarding NBTXR3.
Dr. Kayitalire previously held significant roles at major companies like F-star Biotechnology, Bristol-Myers Squibb, Celgene, and Eli Lilly. He expressed his excitement about the potential of NBTXR3 in changing the landscape of cancer treatment.
NBTXR3 Overview
NBTXR3, a unique oncology product, comprises hafnium oxide nanoparticles. Administered via a single intratumoral injection, it is then activated using radiotherapy. The primary goal is to cause significant tumor cell death in the injected area upon activation, which should then stimulate an adaptive immune response against the cancer.
NANOBIOTIX believes that due to its mode of action, NBTXR3 could be adapted for any solid tumor treatable with radiotherapy and combined with any therapeutic combination, especially immune checkpoint inhibitors.
Current evaluations for NBTXR3 involve its application in various solid tumors either as a standalone or in combination with anti-PD-1 immune checkpoint inhibitors.
Furthermore, NANOBIOTIX has embarked on collaborations to simultaneously develop the product while focusing on its primary developmental pathways. Partnerships include those with The University of Texas MD Anderson Cancer Center, LianBio, and recently with Janssen Pharmaceutica NV.
About NANOBIOTIX
Founded in 2003 and based in Paris, France, NANOBIOTIX is an advanced clinical biotechnology company. They are determined to redefine treatment outcomes for numerous patients by introducing groundbreaking physics-based therapeutic strategies.
The company holds over 20 umbrella patents linked to three distinct nanotechnology platforms. These platforms cater to oncology, bioavailability and biodistribution, and central nervous system disorders. Their principal focus is the development of NBTXR3, which has already received a CE marking in Europe for soft tissue sarcoma treatment under the brand name Hensify®.
While NANOBIOTIX remains a pivotal player in the field, other startups also contribute significantly to advancements in cancer treatment.
Among the many startups in this domain, Nanogenics stands out. They are a leading therapeutic provider that harnesses nanoscale technology and utilises siRNA to treat cancer and fibrotic diseases.
By leveraging their proprietary gene delivery technology, LipTide, they are adept at precisely delivering therapeutic siRNAs. Their premier drug, ECP-102, enhances the efficacy of chemotherapy by increasing the vulnerability of cancer cells to cell death.
Conclusion
The evolving landscape of cancer treatment is witnessing groundbreaking advancements spearheaded by entities like NANOBIOTIX. With the introduction of pioneering therapies, the future holds promise for more effective and diverse solutions in battling this global health crisis. Similarly, the contributions of startups such as Nanogenics emphasise a collective drive in the biotech community to push boundaries, offering hope and a brighter prognosis for patients worldwide.
News
Scientists Have Uncovered Previously Hidden Microbial Activity on Human Skin
The most abundant microbes on your skin may not be the ones doing most of the work. Human skin supports vast communities of bacteria, fungi, and viruses that can influence its protective barrier, immune [...]
Brazilian Tree Compounds Fight COVID-19 on Multiple Fronts
Scientists found compounds in a Brazilian tree that hit SARS-CoV-2 on multiple fronts, revealing a promising new lead in the search for COVID-19 treatments. Researchers have found that galloylquinic acids extracted from the leaves [...]
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
